TADALAFIL IN BENIGN PROSTATIC HYPERPLASIA- PROTOCOL FOR THE SYSTEMATIC REVIEW OF ADVERSE EVENTS
Author(s)
Singh A, Jha RK, Kapoor A, Gupta J
Optum Global Solutions, Noida, India
Presentation Documents
OBJECTIVES: Benign prostatic hyperplasia (BPH) is an age related disorder, however its symptoms begin to appear in some men as early as age 40 years. As per estimates every second person has BPH by the age of 60 and 90% of individuals develop BPH by 85 years. Tadalafil is a selective PDE5 enzyme inhibitor approved to treat men with BPH. The aim is to systematically review the medical literature for randomized control trial and identify the adverse events (AE) associated with tadalafil use in BPH. METHODS: All published randomized controlled trials (RCTs) comparing tadalafil with a placebo or active interventions for the treatment of BPH with or without any co-morbidity (such as but not limited to erectile dysfunction) were sought from PubMed, EMBASE, Cochrane Library, and Google Scholar. Abstracts, titles and then the full-text manuscripts of all selected articles will be retrieved and assessed by two independent reviewers against the eligibility criteria. Disagreements over study inclusion will be resolved through discussion. A pre-designed data extraction form will be used by two reviewers for the extraction of AE and other study findings. Cochrane risk of bias assessment checklist will be used for the risk of bias assessment. An Excel spreadsheet will be used to extract data from the selected articles. Descriptive and quantitative data synthesis will be done for AE reported in all the studies. Meta-analysis will be performed using RevMan (v5.0). RESULTS: Though there are several studies assessing tadalafil use in erectile dysfunction, a systematic review/meta-analysis of the evidence reporting its AE profile when used for the treatment of BPH is lacking. This systematic review registered with PROSPERO (registration number: CRD42014007248) aims to provide the evidence for the AE associate with tadalafil use in BPH indication. CONCLUSIONS: Tadalafil use in BPH has now been increasing over the years. The data from published RCTs will help to identify the AE associated with its use.
Conference/Value in Health Info
2014-09, ISPOR Asia Pacific 2014, Beijing, China
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PUK1
Topic
Epidemiology & Public Health
Topic Subcategory
Safety & Pharmacoepidemiology
Disease
Urinary/Kidney Disorders